Jon Wigginton
Director/Board Member at SUTRO BIOPHARMA, INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bernard A. Fox | M | - |
UbiVac, Inc.
 UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | 19 years |
| Phil Holzer | M | 48 | 11 years | |
| Nadim Ahmed | M | 56 | 3 years | |
| William Newell | M | 66 | 15 years | |
| Hong-Ming Hu | M | - |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | 19 years |
| Jane Chung | F | 53 | 3 years | |
| Nouhad Husseini | M | - | 2 years | |
| Anne-Marie Martin | M | 52 | 2 years | |
| Jay Siegel | M | 71 | 7 years | |
| Helena H. Chaye | M | - |
Kalivir Immunotherapeutics, Inc.
 Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Jeffrey Peters | M | 53 | 9 years | |
| Stephen H. Thorne | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Nicki Vasquez | M | 61 | 9 years | |
| Karen Ferrante | M | 66 | 7 years | |
| Heidi Hunter | F | 65 | 3 years | |
| James Panek | M | 71 | 4 years | |
| Henry Heinsohn | M | - | - | |
| Michael Dybbs | M | 49 | 6 years | |
| Connie Matsui | F | 70 | 5 years | |
| Linda Fitzpatrick | F | 67 | 16 years | |
| David Stump | M | 74 | 11 years | |
| Daniel Petree | M | 68 | - | |
| Christine Siu | F | 47 |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | 3 years |
| John Freund | M | 70 | 10 years | |
| Edward Albini | M | 66 | 11 years | |
| Stephen Webster | M | 63 | 4 years | |
| Joseph Lobacki | M | 65 | 7 years | |
| Grant McFadden | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | 1 years |
| Laura Shawver | M | 66 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | 3 years |
| Scott Jackson | M | 59 | 7 years | |
| Louis Schmukler | M | - | 13 years | |
| Chad Messer | M | - | 2 years | |
| Carlos Lugo | M | - | - | |
| David Pauling | M | - | - | |
| Michael Rosenzweig | M | - |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | - |
| Werner Rubas | M | - | 3 years | |
| Zack Newman | M | - | 11 years | |
| Jeffrey Jones | M | 53 | 2 years | |
| Kurt Rote | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Rose Weldon | F | - | 2 years | |
| Steve Michel | M | - | - | |
| Diana Landa | F | - | 4 years | |
| Richard Jones | M | 72 |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Bernard A. Fox | M | - |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | 19 years |
| Regina Cheng | F | - | 4 years | |
| Craig Berman | M | - | 4 years | |
| Robert Landry | M | 60 | 2 years | |
| Hans-Peter Gerber | M | 61 | 1 years | |
| Alexander Mayweg | M | 49 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | - |
| Kevin Johnston | M | - | 2 years | |
| Joshua Resnick | M | 49 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | - |
| Jacob Chacko | M | 45 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | 3 years |
| Terry Hermiston | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Thomas Woiwode | M | 52 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | - |
| Tom Leonard | M | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | - |
| Darryle Schoepp | M | - |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | 17 years |
| Anne Borgman | M | 56 | 1 years | |
| Stephen Andre | M | 62 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Owen Hughes | M | 49 | 5 years | |
| Alan Fuhrman | M | 67 | 3 years | |
| Alan Bash | M | 52 | - | |
| John E. Celentano | M | 64 | 31 years | |
| Stanford J. Stewart | M | 71 | 8 years | |
| Dinesh C. Paliwal | M | 67 | 8 years | |
| Louis J. Freeh | M | 74 | 8 years | |
| Jeffrey Trigilio | M | 40 | 4 years | |
| Carl Decicco | M | 62 | 10 years | |
| Keith Flaherty | M | 53 | 3 years | |
| Robert Williams | M | 75 | 7 years | |
| Peter Colabuono | M | - | 3 years | |
| Anthony Hooper | M | 69 | 15 years | |
| Shalini Sharp | F | 49 | 5 years | |
| Charles Sigal | M | 72 | 16 years | |
| Robert Obst | M | - | - | |
| Leif Valdemar Johansson | M | 73 | 13 years | |
| Michael Powell | M | 69 | 7 years | |
| Gerald Storch | M | 67 | 12 years | |
| Arnold Lewis Oronsky | M | 83 | 14 years | |
| Matthew Fust | M | 59 | 6 years | |
| Michael Steinmetz | M | 75 | 13 years | |
| Holly Tyson | F | 52 | 8 years | |
| Dimitry Nuyten | M | 48 | 5 years | |
| John Shamsey | M | - | 6 years | |
| John Houston | M | 64 | 6 years | |
| Mary Kay Turner | F | - | 6 years | |
| Scott Gunther | M | 57 | 4 years | |
| Kathryn Zoon | M | 75 |
Center for Cancer Research
| 1 years |
| Randall Owen | M | - | 6 years | |
| Jonathan Yingling | M | 55 | 2 years | |
| Ann Powell | F | 58 | 10 years | |
| Jill DeSimone | F | 68 | 32 years | |
| Kyu-Sung Lee | M | 64 | 5 years | |
| Linda Jordan | F | - | - | |
| Clifford Bechtold | M | - | 2 years | |
| Robert G. Petit | M | 64 | 5 years | |
| Michael Burgess | M | 61 | - | |
| Wendy Dixon | M | 68 | 8 years | |
| Erin E. Lanciani | F | 55 | 5 years | |
| Mark Hollywood | M | 55 | 9 years | |
| Andy Broadway | M | 54 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 93 | 93.00% |
| Switzerland | 7 | 7.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jon Wigginton
- Personal Network
